ST诺泰跌2.47%，成交额2.25亿元，近5日主力净流入664.33万

Core Viewpoint - ST诺泰 is experiencing a decline in stock price, with a recent drop of 2.47% and a total market capitalization of 13.347 billion yuan [1] Group 1: Business Overview - The company specializes in custom products, primarily in the CDMO (Contract Development and Manufacturing Organization) sector, which emphasizes the integration of process development and technical innovation capabilities [2] - ST诺泰 has developed a GLP-1 receptor agonist for diabetes and weight loss, which has received clinical trial approval [2] - The company’s product, Thymosin Alpha 1 injection, is used for the treatment of chronic hepatitis B [3] - The company’s Oseltamivir Phosphate capsules have been approved for treating and preventing influenza [3] - As of the 2024 annual report, overseas revenue accounts for 63.12% of total revenue, benefiting from the depreciation of the RMB [4] Group 2: Financial Performance - For the first half of 2025, ST诺泰 achieved revenue of 1.048 billion yuan, representing a year-on-year growth of 26.07%, and a net profit attributable to shareholders of 310 million yuan, up 36.49% [8] - The company has distributed a total of 362 million yuan in dividends since its A-share listing, with 330 million yuan distributed over the past three years [9] Group 3: Market Activity - The stock has seen a net outflow of 32.0395 million yuan today, with a continuous reduction in main funds over the past three days [5][6] - The average trading cost of the stock is 43.17 yuan, with the current price approaching a resistance level of 42.60 yuan, indicating potential for a price correction if this level is not surpassed [7]